GP6 and stroke disorder: To counteract GPVI function, we exploited glenzocimab (ACT017, Acticor Biotech)46, a humanized antibody fragment (Fab) that has recently completed a phase II trial in stroke patients and is currently examined in a phase II/III trial (ACTISAVE, ClinicalTrials.gov Identifier: NCT05070260).